Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARQTNASDAQ:PTGXNASDAQ:RAPTNASDAQ:ZFGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$8.62+0.3%$10.18$1.76▼$15.21$834.50M1.144.58 million shs1.22 million shsPTGXProtagonist Therapeutics$25.16+2.0%$28.37$13.72▼$33.34$1.47B2.01688,556 shs158,167 shsRAPTRAPT Therapeutics$8.16+4.6%$9.23$6.86▼$27.35$283.97M0.471.14 million shs200,593 shsZFGNZafgen$6.33-2.0%$18.47$0.62▼$2.76$237.19M0.27360,199 shs302,131 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-1.83%-9.10%-7.34%+62.08%-38.20%PTGXProtagonist Therapeutics-4.05%-2.22%-11.93%-1.08%+6.02%RAPTRAPT Therapeutics-1.27%-1.64%-7.14%-69.16%-58.33%ZFGNZafgen-2.01%-0.78%-12.08%+33.83%+40.35%Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics1.7551 of 5 stars3.41.00.00.02.22.50.6PTGXProtagonist Therapeutics1.6054 of 5 stars3.51.00.00.02.62.50.0RAPTRAPT Therapeutics4.0197 of 5 stars4.32.00.03.61.11.70.6ZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics2.75Moderate Buy$26.56208.07% UpsidePTGXProtagonist Therapeutics3.00Buy$36.0043.08% UpsideRAPTRAPT Therapeutics2.50Moderate Buy$25.67214.54% UpsideZFGNZafgenN/AN/AN/AN/ACurrent Analyst RatingsLatest PTGX, RAPT, ZFGN, and ARQT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.004/10/2024RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral3/27/2024RAPTRAPT TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.002/28/2024ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$6.00 ➝ $11.002/28/2024ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $16.002/28/2024PTGXProtagonist TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$34.00 ➝ $37.002/28/2024PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.002/23/2024ARQTArcutis BiotherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $16.002/22/2024RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$61.00 ➝ $10.002/21/2024RAPTRAPT TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/21/2024RAPTRAPT TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$35.00 ➝ $13.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$59.61M14.00N/AN/A$0.94 per share9.17PTGXProtagonist Therapeutics$60M24.44N/AN/A$5.84 per share4.31RAPTRAPT Therapeutics$1.53M185.60N/AN/A$4.27 per share1.91ZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$3.92N/AN/AN/A-439.79%-294.85%-78.57%5/14/2024 (Estimated)PTGXProtagonist Therapeutics-$78.96M-$1.49N/AN/AN/AN/A-27.49%-25.30%5/2/2024 (Estimated)RAPTRAPT Therapeutics-$116.80M-$3.04N/AN/AN/AN/A-63.14%-55.48%5/9/2024 (Estimated)ZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/ALatest PTGX, RAPT, ZFGN, and ARQT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023RAPTRAPT Therapeutics-$0.85-$0.80+$0.05-$0.80N/AN/A2/27/202412/31/2023ARQTArcutis Biotherapeutics-$0.64-$0.72-$0.08-$0.72$11.78 million$13.53 million 2/27/202412/31/2023PTGXProtagonist Therapeutics$0.05$0.44+$0.39$0.44$60.00 million$60.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics2.287.086.80PTGXProtagonist TherapeuticsN/A16.7116.71RAPTRAPT TherapeuticsN/A7.417.41ZFGNZafgen0.266.566.56OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/APTGXProtagonist Therapeutics98.63%RAPTRAPT Therapeutics99.09%ZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics20.70%PTGXProtagonist Therapeutics5.00%RAPTRAPT Therapeutics6.60%ZFGNZafgen14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics29696.81 million76.77 millionOptionablePTGXProtagonist Therapeutics11258.28 million55.36 millionOptionableRAPTRAPT Therapeutics13134.80 million32.50 millionOptionableZFGNZafgen3837.47 millionN/ANot OptionablePTGX, RAPT, ZFGN, and ARQT HeadlinesSourceHeadlineDiagnosing Diabetes: Not So Simplemedscape.com - November 2 at 7:42 AMDo New Weight Loss Meds Mean the End of Bariatric Surgery?medscape.com - October 6 at 8:53 PMPrader-Willi syndromepharmaphorum.com - August 23 at 8:34 PMThe Omnipod 5 System: Trial Results From ENDO 2021medscape.com - August 4 at 8:12 PMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?medscape.com - July 5 at 5:09 PMOral Semaglutide Brings GLP-1s to Primary Caremedscape.com - May 20 at 8:49 PMClinical Trials - Different Phases of the trial News, Research and Latest Updatesmedindia.net - May 20 at 3:49 PMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journalnews.google.com - May 12 at 2:12 PMWeight Loss and Obesity Management Market Insights With ... - Taiwan Newsnews.google.com - May 11 at 3:06 AMGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examinernews.google.com - May 4 at 6:30 PMWeight Loss and Obesity Management Market May See a Big Move ... - Digital Journalnews.google.com - May 2 at 1:13 PMIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocksnews.google.com - May 2 at 8:13 AMThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulationmedscape.com - April 29 at 8:09 PMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Referencenews.google.com - April 22 at 12:41 AMAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journalnews.google.com - April 20 at 9:32 AMAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRnews.google.com - April 14 at 8:21 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMNew ADA Standards: Promoting Healthmedscape.com - April 13 at 7:20 AMAnti-Obesity Drugs Market Set to Register a CAGR of 16.10% and ... - GlobeNewswirenews.google.com - April 10 at 12:56 PMGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030marketwatch.com - April 9 at 10:32 AMAnti-Obesity Drugs Market is expected to rise at A CAGR Of 16.1% during the forecast period 2023 to 2031: Grow - openPRnews.google.com - April 5 at 7:34 AMAnti-Obesity Drugs Market to grow at a CAGR of over 16.1% from 2023 to 2031, reveals Growth Plus Reports - openPRnews.google.com - March 22 at 11:43 AMIndian Anti-Obesity Drug Market 2023 : Projected to Deliver Greater Revenues during the Forecast Period 2028 - openPRnews.google.com - March 1 at 1:17 PMZafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Resultsthestreet.com - February 26 at 7:51 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArcutis BiotherapeuticsNASDAQ:ARQTArcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Protagonist TherapeuticsNASDAQ:PTGXProtagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.RAPT TherapeuticsNASDAQ:RAPTRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.